valproic acid has been researched along with Overweight in 9 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Overweight: A status with BODY WEIGHT that is above certain standards. In the scale of BODY MASS INDEX, overweight is defined as having a BMI of 25.0-29.9 kg/m2. Overweight may or may not be due to increases in body fat (ADIPOSE TISSUE), hence overweight does not equal over fat.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This retrospective longitudinal study included 85 VPA-treated and 93 carbamazepine (CBZ)-treated (as a reference) young patients with epilepsy." | 7.83 | Cytochrome P450 2C19 polymorphisms and valproic acid-induced weight gain. ( Ishitsu, T; Kajiwara, A; Nakagawa, K; Noai, M; Oniki, K; Saruwatari, J; Soraoka, H; Tanamachi, Y, 2016) |
| "Aripiprazole plus a mood stabilizer has minimal impact on metabolic changes in predominantly overweight/obese BPD patients over a 52-week period." | 5.17 | Investigation into the long-term metabolic effects of aripiprazole adjunctive to lithium, valproate, or lamotrigine. ( Baker, RA; Carlson, BX; De Hert, M; Eudicone, JM; Fyans, P; Kemp, DE; Marler, SV; Rahman, Z, 2013) |
| "This retrospective longitudinal study included 85 VPA-treated and 93 carbamazepine (CBZ)-treated (as a reference) young patients with epilepsy." | 3.83 | Cytochrome P450 2C19 polymorphisms and valproic acid-induced weight gain. ( Ishitsu, T; Kajiwara, A; Nakagawa, K; Noai, M; Oniki, K; Saruwatari, J; Soraoka, H; Tanamachi, Y, 2016) |
| "Valproic acid was found to have a significant impact on the worsening of BMI from overweight to obesity (P<0." | 1.40 | The use of psychiatric drugs and worsening body mass index among inpatients with schizophrenia. ( Ching, HY; Wang, PS; Wu, SL, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 7 (77.78) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, PS | 1 |
| Wu, SL | 1 |
| Ching, HY | 1 |
| Hou, YC | 1 |
| Lai, CH | 1 |
| Noai, M | 1 |
| Soraoka, H | 1 |
| Kajiwara, A | 1 |
| Tanamachi, Y | 1 |
| Oniki, K | 1 |
| Nakagawa, K | 1 |
| Ishitsu, T | 1 |
| Saruwatari, J | 1 |
| Płonka-Półtorak, E | 1 |
| Zagrodzki, P | 1 |
| Kryczyk-Kozioł, J | 1 |
| Westermarck, T | 1 |
| Kaipainen, P | 1 |
| Kaski, M | 1 |
| Atroshi, F | 1 |
| Elmslie, JL | 1 |
| Porter, RJ | 1 |
| Joyce, PR | 1 |
| Hunt, PJ | 1 |
| Shand, BI | 1 |
| Scott, RS | 1 |
| Verrotti, A | 1 |
| Manco, R | 1 |
| Agostinelli, S | 1 |
| Coppola, G | 1 |
| Chiarelli, F | 1 |
| Bond, DJ | 1 |
| Kauer-Sant'Anna, M | 1 |
| Lam, RW | 1 |
| Yatham, LN | 1 |
| Kemp, DE | 1 |
| De Hert, M | 1 |
| Rahman, Z | 1 |
| Fyans, P | 1 |
| Eudicone, JM | 1 |
| Marler, SV | 1 |
| Baker, RA | 1 |
| Carlson, BX | 1 |
| Joffe, H | 1 |
| Cohen, LS | 1 |
| Suppes, T | 1 |
| Hwang, CH | 1 |
| Molay, F | 1 |
| Adams, JM | 1 |
| Sachs, GS | 1 |
| Hall, JE | 1 |
1 trial available for valproic acid and Overweight
| Article | Year |
|---|---|
Investigation into the long-term metabolic effects of aripiprazole adjunctive to lithium, valproate, or lamotrigine.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body Weight; Double-Blind Method; Drug | 2013 |
8 other studies available for valproic acid and Overweight
| Article | Year |
|---|---|
The use of psychiatric drugs and worsening body mass index among inpatients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Body Mass Index; Case-Control Studies; Diagnostic and Statistical Manua | 2014 |
The effectiveness of high-dosage amisulpride combined with moderate-dosage sodium valproate treatment for an overweight patient with psychotic bipolar disorder.
Topics: Amisulpride; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Drug Therapy, Combination; Fe | 2014 |
Cytochrome P450 2C19 polymorphisms and valproic acid-induced weight gain.
Topics: Adolescent; Anticonvulsants; Body Mass Index; Carbamazepine; Child; Cytochrome P-450 CYP2C19; Epilep | 2016 |
Does valproate therapy in epileptic patients contribute to changing atherosclerosis risk factors? The role of lipids and free fatty acids.
Topics: Adult; Atherosclerosis; Cohort Studies; Cross-Sectional Studies; Epilepsy; Fatty Acids, Nonesterifie | 2016 |
Comparison of insulin resistance, metabolic syndrome and adiponectin in overweight bipolar patients taking sodium valproate and controls.
Topics: Adiponectin; Adult; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Body Mass Index; Comorb | 2009 |
The metabolic syndrome in overweight epileptic patients treated with valproic acid.
Topics: Adolescent; Anticonvulsants; Body Mass Index; Cardiovascular Diseases; Child; Comorbidity; Dyslipide | 2010 |
Weight gain, obesity, and metabolic indices following a first manic episode: prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM).
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Blood Glucose; Bod | 2010 |
Longitudinal follow-up of reproductive and metabolic features of valproate-associated polycystic ovarian syndrome features: A preliminary report.
Topics: Adolescent; Adult; Antimanic Agents; Bipolar Disorder; Body Mass Index; Female; Follow-Up Studies; H | 2006 |